Chicago Board of Education, Illinois; Tax Secured, General Obligation Nov 01

  • ID: 2033697
  • November 2001
  • Region: Illinois
  • Standard & Poors
1 of 3

The rating on Chicago Board of Education, Ill.'s bonds reflects the following factors: The city's deep and diverse economic base, with growth paralleling that of the nation; A new chief executive officer and board president, but retained financial management team that continues to maintain the schools' financial health as evidenced by four consecutive years of structurally balanced budgets and operations that have consistently outperformed the board's four-year financial plans; A manageable union contract that runs through June 2003, making budgeting predictable; Continued constituent support for board policies resulting from improving education as measured by generally higher test scores; higher enrollment, attendance, and graduation rates; and Lower incidences of truancy, all of which enhance the likelihood of additional achievement. Mitigating factors...

Companies mentioned in this report are:
- Chicago Brd of Ed

Action: New Rating

Standard and Poors RatingsXpress Credit Research provides in-depth coverage of international corporates, financial institutions, insurance companies, utilities, sovereigns and structured finance programs. RatingsXpress Credit Research lets users determine the credit rating of holdings and identify key factors underlying an issuer's creditworthiness, distinguishes the different risk exposures for new and existing deals, and provides an understanding of how their analysts interpret key regulatory, political and environmental events and their economic impact.

Research Type: Full Analysis

Note: Product cover images may vary from those shown
2 of 3

- Chicago Brd of Ed

Note: Product cover images may vary from those shown
3 of 3
Note: Product cover images may vary from those shown




Our Clients

  • Fluidigm Corporation
  • Apple, Inc.
  • CEVA Santé Animale
  • Abbott Laboratories Ltd.
  • Merck Group
  • Allergan Inc.
  • Pfizer Inc.